Document:

KEY HOSPITALITY ACQUISITION CORPORATION
                               4 Becker Farm Road
                           Roseland, New Jersey 07068

                                                              September 13, 2005

Millennium 3 Capital, Inc.
4 Becker Farm Road
Roseland, NJ  07068

Gentlemen:

         This  letter  will  confirm  our  agreement  that,  commencing  on  the
effective date ("Effective Date") of the registration  statement for the initial
public  offering  ("IPO")  of  the  securities  of Key  Hospitality  Acquisition
Corporation  ("Company")  and  continuing  until  (the  "Termination  Date") the
earlier of the  consummation  by the Company of a "Business  Combination" or the
Company's liquidation (as described in the Company's IPO prospectus), Millennium
3  Capital,  Inc.  shall  make  available  to the  Company  certain  office  and
secretarial  services  as may be  required  by the  Company  from  time to time,
situated  at 4 Becker  Farm  Road,  Roseland,  New  Jersey  07068.  In  exchange
therefore,  the Company shall pay  Millennium 3 Capital,  Inc. the sum of $7,500
per month on the Effective  Date and  continuing  monthly  thereafter  until the
Termination Date.

                                         Very truly yours,

                                         KEY HOSPITALITY ACQUISITION CORPORATION

                                         By:  /s/ Jeffrey Davidson
                                            ------------------------------------
                                            Name:   Jeffrey Davidson
                                            Title:  CEO

AGREED TO AND ACCEPTED BY:

MILLENNIUM 3 CAPITAL, INC.

By: /s/ Udi Toledano
   --------------------------
   Name:   Udi Toledano
   Title:  PresidentSETTLEMENT
        AND LICENSE AGREEMENT

       

      This
        Settlement and License Agreement (“Agreement”) is effective and entered into as
        of September 19, 2005 (the “Effective Date”), by and between GE Healthcare Ltd.
        f/k/a Amersham plc, Amersham Health, Inc., and Amersham Health AS, (collectively
        “Amersham”), IMCOR Pharmaceutical Co. f/k/a Photogen Technologies, Inc.
        (“IMCOR”), Alliance Pharmaceutical Corp. (“Alliance”), and Molecular Biosystems,
        Inc. (“MBI”), (Amersham, IMCOR, Alliance, and MBI, collectively “the Parties”).

       

      WHEREAS,
        Amersham possesses intellectual property relating to the formulation, method
        of
        preparing or use of ultrasound contrast products;

       

      WHEREAS,
        until 2003 Alliance possessed intellectual property relating to the formulation,
        method of preparing or use of ultrasound contrast products;

       

      WHEREAS,
        on June 18, 2003, Alliance and IMCOR entered into an Asset Purchase Agreement
        (the “Asset Purchase Agreement”) pursuant to which Alliance sold, conveyed,
        transferred, assigned and delivered to IMCOR all of Alliance’s right, title and
        interest in and to all of Alliance’s tangible and intangible assets for all
        imaging modalities, including (without limitation) (i) all rights related
        to the
        Imagent product, (ii) all patents and other intellectual property related
        to
        such assets, (iii) all claims and causes of action (whether or not then
        asserted) related to such products, patents or intellectual property, and
        (iv)
        all claims and causes of action arising or related to Alliance’s business of
        designing, developing, manufacturing, marketing, selling, licensing, supporting
        and maintaining imaging modalities in connection with Alliance’s imaging and
        diagnostic imaging business;

       

      WHEREAS,
        the Asset Purchase Agreement granted Alliance certain rights with respect
        to the
        Imagent business and related intellectual property after the closing of such
        sale under the conditions, circumstances and terms specified in the Asset
        Purchase Agreement;

       

      WHEREAS,
        IMCOR currently possesses intellectual property relating to the formulation,
        method of preparing or use of ultrasound contrast products; 

       

      WHEREAS,
        there is pending in the United States District Court for the District of
        New
        Jersey a litigation captioned IMCOR
        Pharmaceutical Co. and Alliance Pharmaceutical Corp. v. Amersham Health Inc.,
        Amersham Health AS, and Amersham plc. v. Molecular Biosystems
        Inc.,
        Civil
        Action No. 03-2853 (SRC), (the “Action”), and;

       

      WHEREAS,
        the Parties desire to settle the Action and all existing and potential
        intellectual property disputes relating to certain products.

       

      NOW,
        THEREFORE, in consideration of the foregoing and the covenants, acknowledgements
        and representations contained in this Agreement, the Parties hereby agree
        as
        follows:

       

       

      
        
          
          

        

        
          1/11

          
            

          

        

        
          
          

        

      

       

      
        ARTICLE
          I.  DEFINITIONS

      

       

      1.1.  Definitions.
        For
        purposes of this Agreement, the terms defined here shall have the meanings
        specified below. These terms are intended to encompass both singular and
        plural
        forms.

       

      
        	1.1.1.  	
                “Affiliate”
                  shall mean an entity that directly, or indirectly through one or
                  more
                  intermediaries, controls, or is controlled by, or is under common
                  control
                  with a Party. Without limiting the generality of the foregoing,
“control”
                  shall mean the ownership, directly or indirectly, of fifty percent
                  (50%)
                  or more of the issued share capital or shares of stock entitled
                  to vote
                  for the election of directors, in the case of a corporation, or
                  fifty
                  percent (50%) or more of the equity interests in the case of any
                  other
                  entity or the legal power to direct or cause the direction of the
                  general
                  management and policies of the entity in
                  question.

              

      

       

      
        	1.1.2.  	
                “Amersham
                  Licensed Patents”
                  shall mean Licensed Patents that are owned, obtained, acquired,
                  purchased
                  by or licensed to with a right to sublicense, or in any way under
                  the
                  control or disposal of Amersham, including, but not limited to,
                  all
                  patents asserted by Amersham in the Action, including United States
                  Patent
                  Nos. 5,558,856, 5,558,857, 5,567,412, 5,567,413, 5,569,449, 5,614,169,
                  5,618,514, 5,637,289,, 5,648,062, 5,670,135, 5,817,291, 5,827,502,
                  6,106,806, 6,153,172, and
                  6,544,496.

              

      

       

      
        	1.1.3.  	
                “Field”
                  shall mean ultrasound diagnostic imaging in humans and animals.
                  

              

      

       

      
        	1.1.4.  	
                “Imagent”
                  shall mean the ultrasound contrast product that is the subject
                  of NDA
                  21-191 together with such modification thereto as may be made in
                  connection with such application. 

              

      

       

      
        	1.1.5.  	
                “IMCOR/Alliance
                  Licensed Patents”
                  shall mean Licensed Patents that are owned, obtained, acquired,
                  purchased
                  by or licensed to, with a right to sublicense, or in any way under
                  the
                  control or disposal of IMCOR and/or Alliance, including but not
                  limited to
                  all patents asserted by IMCOR and/or Alliance in the Action including
                  United Sates Patent Nos. 5,540,909, 5,733,527, 6,019,960, 6,056,943,
                  6,280,704, 6,285,339, 6,287,539, and
                  6,706,253.

              

      

       

      
        	1.1.6.  	
                “Licensed
                  Patents”
                  shall mean all present patents and patent applications worldwide,
                  which
                  are issued or pending as of the Effective Date, together with all
                  future
                  patents and patent applications that claim priority (directly or
                  indirectly through other applications) to any patent or patent
                  application
                  pending as of or before the Effective
                  Date.

              

      

       

       

      
        
          
          

        

        
          2/11

          
            

          

        

        
          
          

        

      

       

      
        	1.1.7.  	
                “Optison”
                  shall mean the ultrasound contrast product that is the subject
                  of NDA
                  20-899 together with such modification thereto as may be made in
                  connection with such application. 

              

      

       

      
        	1.1.8.  	
                “Party”
                  shall mean Amersham, Alliance, IMCOR, and/or
                  MBI.

              

      

       

      
        	1.1.9.  	
                “Sonazoid”
                  shall mean any phospholipid-containing ultrasound contrast products
                  that
                  include gaseous C4F10,
                  whether or not combined or modified with any other ingredients,
                  elements
                  or materials.

              

      

       

      
        	1.1.10.  	
                “Territory”
                  shall mean the entire world.

              

      

       

      
        	1.1.11.  	
                “Third
                  Party”
                  shall mean any entity other than Alliance, Amersham, IMCOR, MBI
                  or their
                  Affiliates.

              

      

       

      

      ARTICLE
        II. WORLDWIDE
        GRANT OF INTELLECTUAL PROPERTY RIGHTS

       

      2.1.  IMCOR
        hereby grants Amersham and its Affiliates a fully paid-up, irrevocable
        royalty-free, nonexclusive license, with the right to sublicense, under the
        IMCOR/Alliance Licensed Patents to develop, make, have made, use, sell, offer
        to
        sell, import, or export Optison and/or Sonazoid in the Field in the Territory.
        

       

      2.2.  Alliance
        hereby grants Amersham and its Affiliates a fully paid-up, irrevocable
        royalty-free, nonexclusive license, with the right to sublicense, under the
        IMCOR/Alliance Licensed Patents to develop, make, have made, use, sell, offer
        to
        sell, import, or export Optison and/or Sonazoid in the Field in the Territory.
        

       

      2.3.  Amersham
        hereby grants IMCOR and its Affiliates a fully paid-up, irrevocable
        royalty-free, nonexclusive license, with the right to sublicense, under the
        Amersham Licensed Patents to develop, make, have made, use, sell, offer to
        sell,
        import, or export Imagent in the Field in the Territory. 

       

      2.4.  The
        rights granted hereunder shall extend to IMCOR’s and Amersham’s respective
        distributors, manufacturers, sales agents, exporters, and importers with
        respect
        to activities authorized by and for the benefit of such Party or its Affiliates
        and related to the manufacture, sale, distribution, exportation or importation
        of Imagent, Optison or Sonazoid (as applicable) for or under the direction
        of
        the applicable Party or its Affiliates. The Parties acknowledge that nothing
        in
        this Agreement shall be construed to convey any title or ownership rights
        to the
        Licensed Patents. With the exception of the licenses explicitly granted in
        paragraphs 2.1 through 2.3, no license, release or other right, title or
        interest is granted by implication, estoppel or otherwise.

       

       

      
        
          
          

        

        
          3/11

          
            

          

        

        
          
          

        

      

      
 

      ARTICLE
        III. SETTLEMENT
        OF INTELLECTUAL PROPERTY DISPUTES

       

      3.1.  It
        is the
        intention of the Parties to settle current and potential intellectual property
        disputes pertaining to the Licensed Patents therefore the Parties have
        voluntarily entered into this Agreement. In that connection, the Parties
        shall:

       

      
        	3.1.1.  	
                promptly
                  cause their respective claims in the Action to be dismissed with
                  prejudice
                  by directing their respective counsel to execute and file a Stipulation
                  of
                  Dismissal with prejudice and without costs in the form annexed
                  as Exhibit
                  A; and 

              

      

       

      
        	3.1.2.  	
                withdraw,
                  to the maximum extent allowed by the law in each specific case,
                  all
                  current oppositions brought within or outside the United States
                  against
                  any Licensed Patent with claims which embrace Imagent, Optison,
                  and/or
                  Sonazoid in the Field; 

              

      

       

      3.2.  Amersham
        hereby releases IMCOR, its current Affiliates, and their respective current
        and
        former officers, directors, employees, agents, and attorneys from all claims,
        allegations, damages, obligations, liabilities or expenses of any kind or
        nature
        that it may have against any of them. This releases all claims and obligations
        resulting from anything which has happened up to now, including claims of
        which
        Amersham is not aware, and specifically including without limitation all
        claims
        that were or could have been asserted in the Action, including but not limited
        to all claims of breach of contract, breach of duties of good faith and fair
        dealing, unfair competition, fraud, conversion, unjust enrichment,
        misappropriation of trade secrets, tortious interference with contract,
        antitrust violations, bad faith enforcement and sham litigation, and
        infringement of Amersham Licensed Patents on account of the manufacture,
        use,
        sale, offer for sale, and importation of Imagent up to and including the
        Effective Date.

       

      3.3.  Amersham
        hereby releases Alliance, its current Affiliates, and their respective current
        and former officers, directors, employees, agents, and attorneys from all
        claims, allegations, damages, obligations, liabilities or expenses of any
        kind
        or nature that it may have against any of them. This releases all claims
        and
        obligations resulting from anything which has happened up to now, including
        claims of which Amersham is not aware, and specifically including without
        limitation all claims that were or could have been asserted in the Action,
        including but not limited to all claims of breach of contract, breach of
        duties
        of good faith and fair dealing, unfair competition, fraud, conversion, unjust
        enrichment, misappropriation of trade secrets, tortious interference with
        contract, antitrust violations, bad faith enforcement and sham litigation,
        and
        infringement of Amersham Licensed Patents on account of the manufacture,
        use,
        sale, offer for sale, and importation of Imagent up to and including the
        Effective Date.

       

      3.4.  IMCOR
        hereby releases Amersham, its current Affiliates, and their respective current
        and former officers, directors, employees, agents, and attorneys from all
        claims, allegations, damages, obligations, liabilities or expenses of any
        kind
        or nature that it may have against any of them. This releases all claims
        and
        obligations resulting from anything which has happened up to now, including
        claims of which IMCOR is not aware, and specifically including without
        limitation all claims that were or could have been asserted in the Action,
        including but not limited to all claims of breach of contract, breach of
        duties
        of good faith and fair dealing, unfair competition, fraud, conversion, unjust
        enrichment, misappropriation of trade secrets, tortious interference with
        contract, antitrust violations, bad faith enforcement and sham litigation,
        and
        infringement of IMCOR/Alliance Licensed Patents on account of the manufacture,
        use, sale, offer for sale, and importation of Optison and/or Sonazoid up
        to and
        including the Effective Date.

       

      
        
          
          

        

        
          4/11

          
            

          

        

        
          
          

        

      

      3.5.  Alliance
        hereby releases Amersham, its current Affiliates, and their respective current
        and former officers, directors, employees, agents, and attorneys from all
        claims, allegations, damages, obligations, liabilities or expenses of any
        kind
        or nature that it may have against any of them. This releases all claims
        and
        obligations resulting from anything which has happened up to now, including
        claims of which Alliance is not aware, and specifically including without
        limitation all claims that were or could have been asserted in the Action,
        including but not limited to all claims of breach of contract, breach of
        duties
        of good faith and fair dealing, unfair competition, fraud, conversion, unjust
        enrichment, misappropriation of trade secrets, tortious interference with
        contract, antitrust violations, bad faith enforcement and sham litigation,
        and
        infringement of IMCOR/Alliance Licensed Patents on account of the manufacture,
        use, sale, offer for sale, and importation of Optison and/or Sonazoid up
        to and
        including the Effective Date.

       

      3.6.  
        Alliance
        and IMCOR hereby release Amersham, Hafslund Nycomed ASA, and all successors
        of
        Hafslund Nycomed ASA and their respective current Affiliates, and their
        respective current and former officers, directors, employees, agents, and
        attorneys from any claims related to that certain agreement dated February
        9,
        1995, between Hafslund Nycomed and Alliance entitled “Non-Disclosure and Non-Use
        Agreement.”

       

      3.7.  Amersham
        releases MBI and its respective current and former officers, directors,
        employees, agents, and attorneys from all claims that were or could have
        been
        asserted in the Action including but not limited to claims of breach of
        contract, and breach of duties of good faith and fair dealing.

       

      3.8.  MBI
        releases Amersham, its current Affiliates, and their respective current and
        former officers, directors, employees, agents, and attorneys from all claims
        of
        any kind or nature that it may have against them. This releases all claims
        and
        obligations resulting from anything which has happened up to now, including
        claims of which MBI is not aware, and specifically including without limitation
        all claims that were or could have been asserted in the Action.

       

      3.9.  For
        avoidance of doubt, none of the releases above shall be construed in any
        way to
        limit the ongoing responsibilities and obligations of any Party under that
        certain Settlement Agreement dated May 5, 2000, between Amersham Health AS
        f/k/a
        Nycomed Imaging AS, Amersham Health Inc., f/k/a Nycomed Inc., Mallinckrodt
        Medical Inc., Sonus Pharmaceuticals, Inc. and Molecular Biosystems, Inc (“The
        May 5, 2000 Settlement Agreement”).

       

      
        
          
          

        

        
          5/11

          
            

          

        

        
          
          

        

      

      3.10.  For
        avoidance of doubt, none of the releases above shall be construed in any
        way to
        limit the ongoing responsibilities and obligations of any Party under the
        Optison Product Rights Agreement dated April 9, 2000 between Mallinckrodt
        Inc.
        and MBI, including all amendments thereto (“OPRA”).

       

      3.11.  
        None of
        the releases above shall be construed in any way as being a release of any
        indebtedness to any General Electric Affiliate under any loan agreement,
        security interest, agreement of indebtedness, security interest, or other
        agreement for the loan of money or extension of credit.

       

      3.12.  To
        the
        extent that it may apply to Agreement, the parties waive any and all rights
        under California Civil Code § 1542 (as well as any similar statute or law in any
        other jurisdiction), which section has been duly explained to each of the
        parties by their respective counsel, and which reads as follows: “A general
        release does not extend to claims which the creditor does not know or suspect
        to
        exist in his favor at the time of executing the release, which if known by
        him
        must have materially affected his settlement with the debtor.”

       

      ARTICLE
        IV. FEES,
        PAYMENTS, WARRANTIES, INDEMNIFICATION

       

      4.1.  Amersham
        shall make a one-time payment of $1,200,000 within five business days after
        execution of this Agreement. Said payment shall be by wire transfer of same
        day
        federal funds. Amersham shall make the $1,200,000 payment to the following
        accounts in the following amounts:

       

      
        	4.1.1.  	
                The
                  sum of $1,000,000 to IMCOR 

              

      

       

      Bank
        Name: Bank One

      Bank
        Address: 120 South LaSalle Street, Chicago, IL 60603-3400

      Name
        on
        Account: Grippo & Elden LLC Client Funds Account

      ABA
        Routing #071000013

      Account
        No. 18042465

       

      Contact:
        Linda Williams

      Contact
        Phone: (312) 661-5281

      

      
        	4.1.2.  	
                The
                  sum of $200,000 to Alliance

              

      

       

      Beneficiary
        Name: Alliance Pharmaceutical Corp. 

      Beneficiary
        Account number: 4721-117554 

      Beneficiary
        Bank Routing number: 121000248 

      Beneficiary
        Bank:  Wells
        Fargo Bank

      401
        B
        Street, Suite 2201

      San
        Diego, CA 92101

      Contact: Zena
        S.
        Grant

      Assistant
        Vice President

      Relationship
        Manager

      Wells
        Fargo

      San
        Diego
        Regional

      Commercial
        Banking Group

      (619)
        699-3091 Direct

      (619)
        699-3020 Fax

      

      
        
          
          

        

        
          6/11

          
            

          

        

        
          
          

        

      

      4.2.  Other
        than as set forth in paragraph 4.1 no Party shall have any obligation to
        make
        any payments to the other Party pursuant to this Agreement. Each Party shall
        bear its own costs and expenses, including, without limitation, its attorneys
        fees, relating to any action to be taken or having been taken in respect
        to this
        Agreement.

       

      4.3.  Each
        Party makes the following warranties and representations to the other
        Party:

       

      
        	4.3.1.  	
                each
                  Party is a corporation duly organized and validly existing and
                  in good
                  standing under the laws of the state or country in which it is
                  organized
                  and has all requisite power and authority to enter into and perform
                  this
                  Agreement and the transactions contemplated hereby and to require
                  its
                  Affiliates to abide by its terms and
                  conditions;

              

      

       

      
        	4.3.2.  	
                all
                  requisite corporate action on the part of each Party has been completed
                  for the authorization of the execution and delivery of this Agreement
                  and
                  the performance of the transaction contemplated
                  hereunder;

              

      

       

      
        	4.3.3.  	
                this
                  Agreement is, and such other transactions will be, valid and binding
                  obligations of each Party enforceable in accordance with their
                  respective
                  terms; and

              

      

       

      
        	4.3.4.  	
                the
                  execution, delivery and performance of this Agreement and the consummation
                  of transactions contemplated hereby do not and will not violate
                  the
                  provisions of any Party’s certificate of incorporation or bylaws or
                  similar type documents or the provisions of any note, indenture,
                  lease,
                  license permit or other instrument or obligation or violate any
                  law,
                  order, rule or regulation applicable to it.

              

      

       

      

      ARTICLE
        V. DURATION

      5.1.  The
        term
        of the licenses granted by IMCOR and Alliance shall be until the last to
        expire
        of the IMCOR/Alliance Licensed Patents. 

       

      5.2.  The
        term
        of the license granted by Amersham shall be until the last to expire of the
        Amersham Licensed Patents. 

       

      
        
          
          

        

        
          7/11

          
            

          

        

        
          
          

        

      

      

      ARTICLE
        VI. CONFIDENTIALITY

       

      6.1.  No
        Party
        shall disclose the contents of this Agreement to any other person or entity
        and
        each Party shall retain in confidence the terms and conditions of this
        Agreement, except as necessary to comply with law or the valid order of a
        court
        or agency of competent jurisdiction of a state or federal authority; or to
        the
        extent necessary in any action, suit or proceeding to enforce this Agreement;
        or
        to their respective Affiliates, banks, auditors, accountants, lawyers, and
        any
        other representative of a Party who has a good faith need to know, provided
        that
        any such person or entity to whom disclosure is made must be advised of the
        confidentiality of the information disclosed and agree to keep such information
        confidential. 

       

      6.2.  No
        public
        statements of any kind pertaining to this Agreement may be made except as
        required by law, such as that enforced by the Securities Exchange Commission
        of
        the United States of America, unless the parties otherwise mutually agree
        in
        writing. IMCOR may include a copy of this Agreement with its filings with
        the
        Securities and Exchange Commission. 

       

      

      ARTICLE
        VII. MISCELLANEOUS

       

      7.1.  Notice:
        All
        notices or communications required pursuant to this Agreement shall be in
        writing and shall be deemed to have been duly given upon the date of receipt
        if
        delivered by hand, international overnight courier, confirmed facsimile
        transmission, or registered or certified mail (return receipt requested,
        postage
        prepaid) to the following addresses or facsimile numbers: 

       

      For
        Amersham: GE
        Healthcare Ltd.

      101
        Carnegie Center

      Princeton,
        New Jersey 08540-999

      Attn:
        General Counsel 

      

      For
        Imcor:  IMCOR
        Pharmaceutical Co.

      4660
        La
        Jolla Village Drive, Suite 450

      San
        Diego, CA 92122

      Attn.:
        Jack De Franco, Chief Operating Officer

      

      with
        copies to: Matthew I. Hafter

      Grippo
        & Elden LLC

      111
        South
        Wacker Drive, Suite 5100

      Chicago,
        IL 60606

      

      
        
          
          

        

        
          8/11

          
            

          

        

        
          
          

        

      

      For
        Alliance:  Alliance
        Pharmaceutical Corp.

      4660
        La
        Jolla Village Drive, Suite 825

      San
        Diego, CA 92122

      Facsimile
        No.: (858) 410-5343

      Telephone
        No.: (858) 410-5200

      Attention:
        Duane Roth, Chief Executive Officer

      

      For
        MBI:  Molecular
        Biosystems, Inc. 

      4660
        La
        Jolla Village Drive, Suite 825 

      San
        Diego, California 92122

      Facsimile
        No.: (858) 410-5343

      Telephone
        No.: (858) 410-5200

      Attention:
        Duane Roth, President & Chief Executive Officer

      

      7.2.  Choice
        of Law and Forum:
        The
        Parties agree that this Agreement shall be governed by the laws of the State
        of
        New Jersey without reference to its conflict of laws principles. Any legal
        action or proceeding arising out of or in connection with this Agreement
        shall
        be brought only in the courts of the State of New Jersey or in the United
        States
        District Court for the District of New Jersey, and each Party hereby accepts
        the
        exclusive jurisdiction of such courts for any such matter.

       

      7.3.  Entire
        Agreement:
        This
        Agreement, including all Exhibits attached hereto and all documents delivered
        concurrently herewith, set forth all the licenses, covenants, promises,
        agreements, warranties, representations, conditions, and understandings between
        the Parties hereto and supersede all prior agreements and understandings
        between
        the Parties relating to the subject matter hereof. Notwithstanding the previous
        sentence, this Agreement does not revoke or supersede The May 5, 2000 Settlement
        Agreement, OPRA, or any protective order entered in the Action, all of which
        shall survive the execution of this Agreement. This Agreement, including,
        without limitation, the Exhibits attached hereto, is intended to define the
        full
        extent of the legally enforceable undertakings of the Parties hereto.

       

      7.4.  Severability:
        In the
        event that any provision of this Agreement shall, for any reason, be held
        to be
        invalid or unenforceable in any respect, such invalidity or unenforceability
        shall not affect any other provision hereof, and the Parties shall negotiate
        in
        good faith to modify the Agreement to preserve their original
        intent.

       

      7.5.  Amendment
        and Waiver:
        This
        Agreement may be amended, supplemented, or otherwise modified only by means
        of a
        written instrument signed by all Parties. Any waiver of any rights or failure
        to
        act in a specific instance shall relate only to such instance and shall not
        be
        construed as an agreement to waive any rights or fail to act in any other
        instance, whether or not similar.

       

      7.6.  Headings:
        The
        sections and paragraphs headings contained herein are for the purposes of
        convenience only and are not intended to define or limit the contents of
        said
        sections or paragraphs. 

       

      
        
          
          

        

        
          9/11

          
            

          

        

        
          
          

        

      

      7.7.  Counterparts:
        This
        Agreement may be signed in counterpart, each of which shall be deemed to
        be an
        original. Signatures shall be provided by facsimile transmission, with original
        signatures following by mail.

       

      7.8.  Assignment:
        Neither
        this Agreement nor the licenses granted herein may be assigned to any Third
        Party, except a Party may assign this Agreement to a successor by merger,
        acquisition, or corporate reorganization, and/or in connection with the sale
        or
        other disposition by license, joint venture or otherwise of the entire business
        unit or product(s) to which this Agreement pertains. No Party shall assign,
        by
        operation of law or otherwise, any Licensed Patents to a Third Party without
        such Third Party agreeing to be bound in writing by the licenses granted
        hereunder. 

       

      7.9.  Subsequent
        Acquisitions:
        If,
        after the Effective Date, a Party or its Affiliate either acquires an entity
        or
        acquires substantially all of the assets from an entity, and said entity
        is,
        immediately prior to the date of acquisition, licensed by the other party
        ("Licensor") under one or more Licensed Patents through an existing agreement
        pursuant to which royalties or other payments are made by said entity to
        Licensor, then the license and other rights granted herein to the Acquiring
        Party with respect to said Licensed Patents shall apply to products manufactured
        by said entity or through the use of said assets, provided that such royalties
        or other payments shall continue to be made by the Acquiring Party or said
        entity to the Licensor with respect to such products notwithstanding that
        the
        Acquiring Party may have been licensed for the same products before the
        acquisition.

       

      
        
          
             

          

          
          

        

        
          10/11

          
            

          

        

        
          
          

        

      

      IN
        WITNESS WHEREOF, the undersigned Parties have duly executed and delivered
        this
        Agreement as of the date first written above.

       

      

      

      
        	
                GE
                  Healthcare Ltd.

                 

                By:
                  /s/
                  Jeffrey J. Freedman

                 

                Name:
                  Jeffrey J. Freedman

                 

                Title:
                  Attorney-in-fact

                 

                Date:
                  9/20/05

              	
                Amersham
                  Health AS

                 

                By:
                  /s/
                  Ase Aulie Michalet 

                 

                Name:
                  Ase Aulie Michalet

                 

                Title:
                  President

                 

                Date:
                  9/21/05

              

      

      

      

      
        	
                Amersham
                  Health Inc.

                 

                By:
                  /s/
                  Daniel L. Peters

                 

                Name:
                  Daniel L. Peters

                 

                Title:
                  President

                 

                Date:
                  9/20/05

              	
                IMCOR
                  Pharmaceutical Co.

                 

                By:
                  /s/
                  Brian M. Gallagher 

                 

                Name:
                  Brian M. Gallagher

                 

                Title:
                  Chairman of the Board

                 

                Date:
                  9/19/05

              

      

      

      

      
        	
                Alliance
                  Pharmaceutical Corp.

                 

                By:
                  /s/
                  Duane J. Roth 

                 

                Name:
                  Duane J. Roth

                 

                Title:
                  Chairman & CEO

                 

                Date:
                  9/19/05

              	
                Molecular
                  Biosystems, Inc.

                 

                By:
                  /s/
                  Duane J. Roth 

                 

                Name:
                  Duane J. Roth

                 

                Title:
                  Manager

                 

                Date:
                  9/19/05

              

      

      

      

      
        
          
             

          

          
          

        

        
          11/11

          
            

          

        

        
          
          

          
          

        

      

EXHIBIT
      A

       

      UNITED
        STATES DISTRICT COURT

      DISTRICT
        OF NEW JERSEY

       

      
        	
                 

                IMCOR
                  PHARMACEUTICAL CO. and

                ALLIANCE
                  PHARMACEUTICAL CORPORATION,

                Plaintiffs/Counterclaim-Defendants,

                 

                v.

                 

                AMERSHAM
                  HEALTH INC., 

                AMERSHAM
                  HEALTH AS, 

                and
                  AMERSHAM plc,

                Defendants/Counterclaim-Plaintiffs,

                 

                v.

                 

                MOLECULAR
                  BIOSYSTEMS, INC.,

                Counter-Claim
                  Defendant.

              	
                 

                 

                 

                 

                Civil
                  Action No. 03-2853 (SRC)

                 

                Honorable
                  Stanley R. Chesler

                 

                Magistrate
                  Judge Tonianne Bongiovanni

                 

              

      

      

      STIPULATION
        OF DISMISSAL WITH PREJUDICE

      

      This
        matter having been amicably adjusted by and between the parties, it is hereby
        stipulated and agreed that the above-captioned action, and all claims and
        counterclaims asserted herein, shall be and hereby are dismissed with prejudice
        and without costs. 

      

       

       

      
        	
                KENYON & KENYON

                1 Broadway

                New York, NY 10004-1007

                 

                By:____________________

                 

                 

                DATED: September , 2005 

              	
                NORTON
                  & DIEHL LLC

                77
                  Brant Avenue, Suite 110

                Clark,
                  New Jersey 07066

                

                By:____________________

                 

                

                DATED:
                  September , 2005

              

      

       

       

      

      

      SO
        ORDERED this __________ day of September, 2005.

      

      ___________________________________

      STANLEY
        R. CHESLER, U.S.D.J.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]